Invivyd Förvaltning
Förvaltning kriterier kontrolleras 2/4
Invivyd VD är Bill Duke, utsedd i Sep 2023, har en mandatperiod på 2.67 år. totala årliga ersättningen är $ 2.14M, bestående av 22.7% lön 77.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.038% av företagets aktier, värda $ 150.81K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.3 år respektive 3 år.
Viktig information
Bill Duke
Verkställande direktör
US$2.1m
Total ersättning
| VD-lön i procent | 22.65% |
| Anställning som VD | 2.7yrs |
| Ägande av VD | 0.04% |
| Ledningens genomsnittliga anställningstid | 2.3yrs |
| Styrelsens genomsnittliga mandatperiod | 3yrs |
Senaste uppdateringar av ledningen
Recent updates
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside
Narrative Update on Invivyd Analysts have modestly adjusted their price view on Invivyd, with the updated fair value holding at $10.00. Small tweaks to discount rate, revenue growth, profit margin assumptions, and a higher future P/E estimate of about 282x refine the underlying model rather than signal a major shift in conviction.Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
Mar 20IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions around revenue growth of 71.06%, a profit margin of 5.97% and a future P/E of 266.11x. These assumptions result in a revised fair value estimate of $10.00 per share.IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside
Analysts have kept their fair value estimate for Invivyd steady at $10.00. A slightly lower discount rate and modestly softer profit margin outlook, paired with a marginally higher future P/E assumption, reflect a more finely balanced view of the company’s risk and earnings potential.IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside
Analysts have trimmed their price target on Invivyd to US$10, citing updated assumptions that include a slightly higher discount rate, modestly reduced profit margin expectations, and a higher future P/E multiple. What's in the News FDA granted Fast Track designation for VYD2311, Invivyd's vaccine alternative monoclonal antibody candidate for prevention of COVID in individuals with underlying risk factors for severe disease, aligning the program with an expedited U.S. regulatory process (Key Developments).Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk
Jan 29
IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative
Analysts have lifted their price target on Invivyd to US$10 from US$5, citing the launch of the REVOLUTION clinical program for VYD2311 as a key driver behind their updated view. Analyst Commentary Analysts are reacting to the REVOLUTION program for VYD2311 as a key event for Invivyd, and the updated US$10 price target reflects how they are recalibrating risk and potential upside around this new clinical path.IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential
Narrative Update on Invivyd Analysts have lifted their price target on Invivyd to US$10 from US$5, pointing to the launch of the REVOLUTION clinical program for VYD2311 as a key factor that they believe strengthens the company’s regulatory and commercial position. Analyst Commentary Recent Street research around Invivyd has focused squarely on the launch of the REVOLUTION clinical program for VYD2311, with bullish analysts recalibrating their expectations for the company’s potential market position and execution risk.IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking
Nov 29IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook
Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead
Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Oct 14Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge
Aug 22Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.
Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025
The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.I See The Bull Case For Invivyd, But I'm Not Married To It
Feb 04Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
Feb 01Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation
Jul 16Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?
Mar 29We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Oct 24We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Jul 04Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
Mar 19Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?
Nov 19Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$485k | -US$52m |
| Sep 30 2025 | n/a | n/a | -US$60m |
| Jun 30 2025 | n/a | n/a | -US$110m |
| Mar 31 2025 | n/a | n/a | -US$143m |
| Dec 31 2024 | US$636k | US$480k | -US$170m |
Ersättning vs marknad: Bill s total kompensation ($USD 2.14M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.50M ).
Ersättning vs inkomst: Ersättningen för Bill har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Bill Duke (53 yo)
2.7yrs
Anställning
US$2,141,222
Kompensation
Mr. William E. Duke, Jr., also known as Bill, M.B.A., serves as Chief Financial Officer and Principal Accounting Officer of Invivyd, Inc. since September 2023 and serves as its Principal Executive Officer...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CFO, Principal Accounting Officer & Principal Executive Officer | 2.7yrs | US$2.14m | 0.038% $ 150.8k | |
| Chief Legal Officer & Corporate Secretary | 4.5yrs | US$2.49m | 0.064% $ 255.1k | |
| Chief Commercial Officer | 2yrs | US$2.10m | 0.042% $ 164.8k | |
| Chief Scientific Officer | 3.1yrs | US$2.16m | 0.040% $ 160.3k | |
| Chief Communications Officer | less than a year | inga uppgifter | inga uppgifter | |
| Chief Human Resources Officer | 3.3yrs | US$1.59m | 0.038% $ 150.8k | |
| Senior Vice President of Regulatory Affairs | less than a year | inga uppgifter | inga uppgifter | |
| Senior Vice President of Finance | no data | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | less than a year | inga uppgifter | inga uppgifter |
2.3yrs
Genomsnittlig anställningstid
51.5yo
Genomsnittlig ålder
Erfaren ledning: IVVD s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Independent Director | 5.6yrs | US$84.46k | inga uppgifter | |
| Independent Director | 2yrs | US$101.61k | 0.018% $ 70.0k | |
| Independent Chairperson of the Board | 3.9yrs | US$125.96k | inga uppgifter | |
| Independent Director | 1.2yrs | US$110.16k | inga uppgifter | |
| Independent Director | less than a year | US$134.35k | inga uppgifter | |
| Independent Director | 3.9yrs | US$87.96k | 0% $ 0 |
3.0yrs
Genomsnittlig anställningstid
50yo
Genomsnittlig ålder
Erfaren styrelse: IVVD s styrelse anses inte vara erfaren ( 3 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 21:10 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Invivyd, Inc. bevakas av 6 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Jason Kolbert | D. Boral Capital LLC. |